Blepharospasm Patient Survey for Patients With Blepharospasm

Completed

Conditions studied: Blepharospasm

In brief

The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Key facts

Study ID

NCT01686061

Run by

Merz Pharmaceuticals GmbH

People needed

124

Starts

2012-09-01

Expected to finish

2013-04-01

Last updated by the study team

2022-10-28

Who can join

Age: 18 and older, up to 81. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subject aged > 18 years and < 81 years
• Documented clinical diagnosis of blepharospasm
• Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA

You may not qualify if…

• Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles

Where it is running

• Merz Investigative Site #0007 — Fountain Valley, California, United States
• Merz Investigative Site # 0002 — Sarasota, Florida, United States
• Merz Investigative Site # 0001 — Boston, Massachusetts, United States
• Merz Investigative Site #003 — Durham, North Carolina, United States
• Merz Investigative Site # 0006 — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.